Post-chemotherapy myelosuppression after Chinese medicine compound intervention chemotherapy based on patent mining
10.3969/j.issn.1673-9701.2025.08.019
- VernacularTitle:基于专利挖掘的中药复方干预化疗后骨髓抑制研究
- Author:
Wang JIN
1
;
Sheng LI
;
Yinping PAN
Author Information
1. 浙江鑫达医院肿瘤科,浙江湖州 313000
- Publication Type:Journal Article
- Keywords:
Post-chemotherapy myelosuppression;
Patents;
Compound TCM;
Data mining
- From:
China Modern Doctor
2025;63(8):70-74
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prescription compatibility of post-chemotherapy myelosuppression after traditional Chinese medicine(TCM)compound patent,and provide reference for research and development of Chinese medicine.Methods Search formulary data of post-chemotherapy myelosuppression after TCM compound patent from the patent database from buiding to October 29,2024.A total of 63 patents were included,involving 668 flavors of TCM.The frequency,properties and taste statistics,association rules and cluster analysis were conducted,and core network was constructed.Results Chinese medicine flavor were mainly cool,warm,sweet,bitter,xin,mostly return to the lung,liver,spleen three classics,high frequency drugs included Huangqi,Danggui,etc.Common medicine included Huangqi-Danggui,Huangqi-Baizhu,etc.Conclusion This study uses data mining to explore the prescription compatibility rule of post-chemotherapy myelosuppression after TCM compound patent intervention.Huangqi and Danggui are core Chinese medicine treating post-chemotherapy myelosuppression.
